Gemtuzumab ozogamicin (Mylotarg®) in children with refractory or relapsed acute myeloid leukemia
D. Reinhardt, S. Diekamp, G. Fleischhack, S. Corbacioglu, H. Jürgens, M. Dworzak, G. Kaspers, U. Creutzig, C. M. Zwaan
Research output: Contribution to journal › Article › peer-review
41Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Gemtuzumab ozogamicin (Mylotarg®) in children with refractory or relapsed acute myeloid leukemia'. Together they form a unique fingerprint.